OptiBiotix Health (OPTI)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

18.75p
   
  • Change Today:
      0.63p
  • 52 Week High: 39.00p
  • 52 Week Low: 6.00p
  • Currency: UK Pounds
  • Shares Issued: 97.94m
  • Volume: 116,607
  • Market Cap: £18.36m

Deal with Barclays    Trade now with Barclays Stockbrokers

OptiBiotix inks ingredient deal with Tata Chemicals

By Josh White

Date: Monday 23 Oct 2023

LONDON (ShareCast) - (Sharecast News) - Life sciences developer OptiBiotix Health announced a significant agreement with Tata Chemicals on Monday, that would see its proprietary 'Fossence' product incorporated into their 'SlimBiome' and 'LeanBiome' product lines, specifically tailored for the Indian market.
The AIM-traded firm said the deal would see Tata's Fossence - a proprietary short chain fructo-oligosaccharide (FOS) - into OptiBiotix's SlimBiome and LeanBiome products, customised to cater to the demands of the Indian consumer base.

It said Fossence would directly replace the FOS currently used in SlimBiome products available in other markets.

The board said the integration was a strategic move grounded in scientific substantiation, aiming to bring forth the well-documented health benefits of FOS to the Indian market.

It said Tata Chemicals, listed on the Indian stock exchange, is an integral part of the Tata Group, which employs over one million people and recorded annual revenue of around $300bn in 2022.

As part of the collaboration, Tata Chemicals granted approval for the incorporation of the Fossence logo on products containing SlimBiome in India, introducing a branded ingredient from a reputable source to Indian consumers.

"We are pleased to report this agreement with Tata Chemicals which creates the opportunity to bring products containing Tata's proprietary Fossence in SlimBiome and LeanBiome to the Indian market," said chief executive officer Stephen O'Hara.

"Tata Chemicals is one of India's leading suppliers of food ingredients with many well-known and respected brands.

"Fossence's established health benefits with Indian consumers and its trusted brand combined with SlimBiome's strong science, clinical studies, and excellent customer reviews will help reduce hunger and food cravings to support the weight management efforts of India's 135 million obese men and women."

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

OPTI Market Data

Currency UK Pounds
Share Price 18.75p
Change Today 0.63p
% Change 3.45 %
52 Week High 39.00p
52 Week Low 6.00p
Volume 116,607
Shares Issued 97.94m
Market Cap £18.36m

OPTI Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
59.58% above the market average59.58% above the market average59.58% above the market average59.58% above the market average59.58% above the market average
92.16% above the sector average92.16% above the sector average92.16% above the sector average92.16% above the sector average92.16% above the sector average
Price Trend
5.62% below the market average5.62% below the market average5.62% below the market average5.62% below the market average5.62% below the market average
33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average
Income Not Available
Growth
96.71% below the market average96.71% below the market average96.71% below the market average96.71% below the market average96.71% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average

OPTI Dividends

No dividends found

Trades for 28-May-2024

Time Volume / Share Price
16:13 8,000 @ 18.82p
15:54 9,367 @ 18.82p
15:49 315 @ 18.37p
14:29 2,564 @ 18.37p
13:06 7,515 @ 18.90p

OPTI Key Personnel

CEO Stephen O'Hara
Finance Director Graham Myers

Top of Page